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We have previously communicated that heparin released asymmetric acetylcholinesterase (AChE) from 
cholinergic synapses. Here we report studies showing that heparin, besides releasing asymmetric AChE from 
the skeletal muscle extracellular matrix (ECM), specifically solubilizes a dermatan sulfate proteoglycan 
(DSPG) which accounts for more than 95% of the 35S-released material. The co-solubilization of AChE and 
the proteoglycan opens up the possibility that both macromol~ules could be involved in the formation of 
the soluble AChE complex observed after incubation of muscle homogenate with heparin. Our results sug- 
gest a possible association between asymmetric AChE and DSPG at the muscle ECM, moreover this work 
is the first report of the existence of DSPG at the skeletal muscle cell surface. 
Acetylcholinesterase; Heparin; Dermatan sulfate proteoglycan; (Muscle extracellular matrix) 
1. INTRODUCTION 
Acetylcholi~esterase (EC 3.1.1.7) is the enzyme 
responsible for the hydrolysis of the neuro- 
transmitter acetylcholine. The enzyme exercises 
this role at synaptic junctions where it is thought to 
be bound via extracellular HSPGs to muscle, elec- 
tric organ and neuronal cells [l-3]. The AChE at 
the synaptic ECM is displaced by the action of 
exogenously applied heparin through a mechanism 
involving competition for enzyme binding between 
the polyanion and the endogenous protein-linked 
GAG [4-61. We have recently found that the ECM 
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of rat skeletal muscles contained a HSPG of 5 x 
lo5 Da which is apparently concentrated at the 
neuromuscular junction 171. The aim of this paper 
is to examine whether endogenous HSPGs could 
be displaced from the muscle ECM on addition of 
heparin; this is important because heparin re- 
moved AChE from the ECM by a mechanism that 
involves the formation of soluble complex between 
the GAG (HSPG?) and the as~metric AChE 
[2,4&l. 
We report here that heparin solubilizes asym- 
metric AChE and DSPG, but not HSPG, from the 
rat neuromuscular junction. This result is impor- 
tant for two reasons, (i) it is the first evidence link- 
ing AChE to DSPG, and (ii) it provides direct 
evidence for the presence of DSPG in the ECM of 
rat skeletal muscle. 
2. MATERIALS AND METHODS 
The following chemicals were used: chondroitin 
sulfate from shark and whale cartilage, heparin 
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from bovine lung and chondroitinase ABC and AC 
(Sigma); guanidine-HCl (Bethesda Research 
Labs); Naz3’S04 (100 Ci/mmol) was obtained 
from New England Nuclear. Other reagents, where 
not specified, were obtained from commercial 
sources. 
In all experiments male Sprague-Dawley rats 
(200 g body wt) were used. The rats were injected 
i.p. with a total of 10 mCi of [35S]sulfate in saline. 
Four injections were carried out during the first 
12 h. 
2.1. Preparation of ECM-like material 
A detergent-insoluble fraction enriched in basal 
lamina components was prepared by modifications 
of previous procedures [8,9]. Rat skeletal muscles 
were homogenized in 10 mM Tris-HCl buffer, pH 
7.4, containing 20 U/ml aprotinin, 5 mM 
benzamidine-HCl, 100 mM 6-aminohexanoic acid, 
0.5% (v/v) Triton X-100. The homogenate was 
centrifuged at 15000 x g for 15 min. The 
precipitate was resuspended in the same 
homogenization medium and centrifuged again. 
This procedure was repeated three times, and the 
final insoluble precipitate ECM-like material was 
used for the experiments described in this paper. 
2.2. Characterization of proteoglycans 
The 35S-material solubilized by heparin from the 
muscle ECM, was diluted with 8 M urea, 0.2 M 
sodium chloride and 0.05 M sodium acetate, pH 
6.0. The sample was then applied to a DEAE- 
Sephacel column pre-equilibrated in the same 8 M 
urea buffer with the addition of 0.5% (v/v) Triton 
X-100. After sample application, the column was 
washed with 5-10 ml of the same buffer, and then 
eluted with a continuous NaCl gradient in the same 
solvent using a total volume of 40 ml [lo]. A bed 
volume of 3 ml was used for the DEAE-Sephacel 
column. Analytical Sepharose CL4B chromatog- 
raphy was carried out in columns of 0.7 x 120 cm 
prepared in 1% SDS, 0.1 M NaCl and 50 mM 
Tris-HCI buffer, pH 8.0. Samples were applied to 
columns together with previously fractionated 
Blue Dextran 2000 (Pharmacia) and phenol red, 
respectively to mark the void and total volumes. 
2.3. Enzymatic and chemical treatments 
Chondroitinase digestion of 35S-labelled pro- 
teoglycans was done in 50 mM Tris-HCl buffer 
160 
(pH 7.0) containing 100 mM NaCl. Digestion with 
0.1 U/ml was carried out for 4 h at 37°C [I 11. 
Degradation of heparan sulfate was done by 
nitrous acid treatment using reaction ‘A’ of Lin- 
dahl et al. [12]. GAG chains free from the protein 
were obtained from the proteoglycans by a mild 
alkali treatment (24 h at 37°C in 100 mM NaOH 
and 1 M NaBH4) [13]. 
2.4. AChE assay and sucrose gradients 
AChE activity was measured as in [14]. Velocity 
sedimentation in 5-20070 sucrose gradients was car- 
ried out as described [15]. 
3. RESULTS 
If it is assumed that asymmetric AChE is bound 
to polysaccharide ‘receptors’, it may be postulated 
that added heparin would displace completely the 
600 
I I I I I I 
0 02 04 06 08 10 
HEPARIN CONCENTRATION (mghl) 
Fig. 1. Solubilization of “S-1abelled polysaccharide and 
asymmetric AChE from ECM-like material of rat 
skeletal muscles. A detergent-insoluble ECM fraction 
was incubated in50 mM Tris-HCl, pH 8.4. Heparin was 
added to the different samples to obtain the final 
concentration shown in the figure. After homogeniza- 
tion, the samples were centrifuged at 15000 x g during 
15 min and the AChE activity (O---O) was determined 
in the supernatant. In parallel experiments the 35S- 
radioactivity released by heparin was also evaluated 
(M). In each case a point represents the average of 
three different experiments. The inset shows the velocity 
sedimentation of the AChE molecular forms solubilized 
by heparin (M) after separation in 520% sucrose 
gradients [ 1,151. The arrow indicates the sedimentation 
position of ,8-galactosidase (16.1 S). 
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particular surface-bound proteoglycan. As shown 
in fig. 1, the addition of heparin to skeletal muscle 
ECM [2,8] displaced around 35% of the total en- 
dogenous 35S-labelled polysaccharide and most of 
the asymmetric AChE (see inset in fig. 1). Maximal 
amounts of 35S-labelled polysaccharide and AChE 
were released by heparin at 0.2-0.3 mg/ml. All the 
class I and part of the class II forms of AChE were 
solubilized by heparin (not shown). 
[35S]Sulfate-labelled polysaccharide released by 
heparin (1 mg/ml) was analyzed by DEAE- 
Sephacel chromatography (fig.2A). This method 
has proved to be very effective in separating 
heparan sulfate from dermatan sulfate pro- 
teoglycans because of the large charge density dif- 
ference in the two classes of GAGS [lo]. Most of 
the bound material to the DEAE-Sephacel column 
eluted at a salt concentration of 0.5 M NaCl. In 
order to know how many kinds of proteoglycans 
of similar charge and different size were released 
by heparin, the above DEAE peak was pooled and 
analyzed by Sepharose CL-4B chromatography in 
4 M guanidine-HCl. The elution profile is shown 
in fig.2B (o--o). The 35S-labelled polysaccharide 
eluted at K,, = 0.6 which corresponds to a single 
species of 1M, = OS-O.8 x 10’ [la]. Incubation of 
this material with alkaline borohydride released 
polysaccharide chain from the core protein 
(fig.2B, O---O) indicating that this 35S-labelled 
material represents a proteoglycan. 
In order to determine the nature of this pro- 
35 teoglycan, the S- labelled material solubilized by 
heparin from the muscle ECM was concentrated 
and submitted to different mucopolysaccharides 
and chemical treatments. When the “S-1abelled 
proteoglycan was treated with nitrous acid 
(degrades heparan sulfate and heparin) and 
chromatographed on Sepharose CL4B (fig.3A), 
almost all the material eluted at a similar position 
to that of the control (fig.2B, o--o). This result 
indicated that a HSPG was not released by 
heparin. When the 35S-labelled material was 
treated with chondroitinase ABC (degrades chon- 
droitin and dermatan sulfate) more than 95% of 
the 35S-labelled proteoglycan was hydrolyzed and 
the fragments eluted at the total volume of the col- 
umn (fig.3B). Finally when the “S-1abelled 
material solubilized by heparin was treated with 
chondroitinase AC II (degrades only chondroitin 
sulfate [ll]) no change in the elution position of 
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Fig.2. Characterization of the 35S-labelled polysaccha- 
ride released by heparin as a proteoglycan. (A) DEAE- 
Sephacel chromatography: 3sS-labelled material solu- 
bilized by heparin from a muscle ECM fraction, was 
diluted in 8 M urea, 0.2 M NaCl and was then applied 
to a DEAE-Sephacel column previously equilibrated in 
the same solution. The material bound to the column 
was eluted in a linear gradient of 0.2-0.9 M NaCI. (B) 
Sepharose CL-4B: The 3’S-labelled material bound to 
the DEAE-Sephacel column, was concentrated and 
applied to a Sepharose CL-4B (M). The proteogly- 
can nature of the 35S-labelled material released by 
heparin was demonstrated after treatment of the 
material bound to the DEAE-Sephacel column with 
sodium borohydride (O---O). Under these conditions 
the free GAG chains eluted from the Sepharose CL-4B 
after the untreated material (Z& 0.72 against Kay 0.54). 
The recovery of radioactivity from both columns was 
better than 90%. The two arrows at K,, 0.25 and 0.41 
corresponded to the elution of the two major HSPGs 
present in the muscle ECM [7]. 
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Fig.3. The 35S-labeiled proteoglycan released by heparin 
is a DSPG. The 35S-labelled proteoglycan solubilized by 
heparin from the skeletal muscle ECM was treated with 
(A) nitrous acid, which degrades heparan sulfate and 
heparin; (B) chondroitinase ABC, which degrades 
chondroitin and dermatan sulfate; and (C) chondroiti- 
nase AC XI, which only degrades chondroitin sulfate. 
The products of these reactions were filtrated in Se- 
pharose CL-4B (pre-equilibrated in 50 mM Tris-HCI, 
pH 8.0,O.l M NaCl and 1% SDS). The recovery in the 
three columns was around 87 and 95%. 
the 35S-labelled proteoglycan was observed in the 
Sepharose CL4B (fig.3C). This result indicates 
that heparin releases from the muscle ECM a 
DSPG previously unknown. 
4. DISCUSSION 
Our results clearly demonstrate that heparin co- 
solubilizes both the asymmetric AChE and a 
DSPG from the skeletal muscle ECM. This result 
was unexpected, in fact; following the rationale 
that heparin released AChE by the removal of the 
polysaccharide receptor involved in its anchorage, 
we anticipated the solubilization of HSPG. 
However, this was not the case and almost all the 
35S-labelled proteoglycan solubilized corresponds 
to DSPG, a proteoglycan not previously observed 
in the basement membranes of skeletal muscles. 
The significance of the co-liberation of the asym- 
metric AChE and a dermatan sulfate type of pro- 
teoglycan is uncertain and of course does not 
necessarily prove that DSPG is bound to AChE in 
situ, in fact its release might well fortuitously coin- 
cide with that of AChE. Alternatively, our results 
could be related to a possible interaction between 
both macromolecules in the muscle ECM. 
fn studies on the binding of Discopyge asym- 
metric AChE to bovine endothelial cells, we have 
previously shown that treatment with chon- 
droitinase ABC (degrades both chondroitin and 
dermatan sulfate) determines ome decrease in the 
binding of the asymmetric AChE to such cefls [ 171, 
this result is interesting because ~hondroitin sulfate 
was not able to dissociate previously bound AChE, 
suggesting that besides HSPG, dermatan sulfate 
but not chondroitin sulfate proteoglycans could 
also be involved in the association of AChE to en- 
dothelial cells. In the case of Cz mouse myotube 
cultures however, treatment with chondroitin~e 
ABC did not release asymmetric AChE, indicating 
that neither chondroitin sulfate proteoglycan nor 
DSPGs are involved in the anchorage of the 
esterase to mouse myotubes [18]. The same was 
true for experiments carried out with purified 
cholinergic basal lamina from L)iscopyge electric 
organ [ZJ. 
DSPGs which differ greatly in size and structure 
are present in the basement membranes, plasma 
membranes, and ECM of a variety of different 
normal and neoplastic tissues [19]. DSPGs of 
relatively large size are components of the base- 
ment membranes of teratocarcinoma ceils [20,21], 
however the most widely distributed DSPGs are 
the small, interstitial proteoglycans present in the 
ECM of fibrous connective tissues [22]. 
The DSPG solubilized by heparin from the mus- 
cle ECM is a small proteoglyc~ of 50~- 
80000 Da, a size consistent with that of a potential 
aggregating factor for the solubilized asymmetric 
AChE. In this context it is interesting to mention 
that different laboratories [4,6] have reported that 
heparin released asymmetric AChE, not as in- 
162 
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dependent macromolecules, but as soluble com- 
plex of 24-30 S. Since a wide variety of 
polyanions, including heparin [23], form com- 
plexes with asymmetric AChE, it is possible that 
the soluble AChE-polysaccharide complex could 
be formed by the association of asymmetric AChE 
and the small DSPGs identified in the present com- 
munication. However further work is necessary to 
establish whether dermatan sulfate presents a 
higher affinity for the enzyme than heparin. 
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